Concepedia
Statistics
Publications
58
Citations
6.1K
H-Index
38
Active since
1983
Affiliations
Pfizer (United States)(Current)
Virginia Commonwealth University Medical Center
University of California San Diego
Uniformed Services University of the Health Sciences
Amplyx Pharmaceuticals (United States)
Robert S. Mansbach is an author at Pfizer (United States) specializing in pharmacology, neuropharmacology, and medicine.
Publications per year
1983–2022
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Jotham W. Coe, Paige R. Brooks, Michael G. Vetelino et al. · Journal of Medicinal Chemistry · 2005 · 933 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +17
Dopaminergic stimulation disrupts sensorimotor gating in the rat
Robert S. Mansbach, David Braff · Psychopharmacology · 1988 · 607 citations
Life Sciences, Neurobiology, Neuroscience +12
Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
Hans Rollema, Leslie K. Chambers, J.W. Coe et al. · Neuropharmacology · 2006 · 535 citations
Public Health, Pharmacology, Pharmacotherapy +14
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.
David W. Schulz, Robert S. Mansbach, Jeffrey Sprouse et al. · Proceedings of the National Academy of Sciences · 1996 · 379 citations
Medicine, Neuroscience, Pharmacology +17
Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat*1
Robert S. Mansbach · Neuropsychopharmacology · 1989 · 378 citations
Medicine, Neuroscience, Pharmacology +8
1–5 of 58